|
Federal Register
Notices > Importers >
Lipomed Inc.
FR Doc E6-11688 [Federal Register: July 24, 2006 (Volume 71, Number 141)]
[Notices] [Page 41837-41838] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24jy06-111]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21
U.S.C. 958(i), the Attorney General shall, prior to issuing a
registration under this Section to a bulk manufacturer of a controlled substance
in Schedule I or II and prior to issuing a regulation under 21
U.S.C. 952(a) (2)
(B) authorizing the importation of such a substance, provide manufacturers
holding registrations for the bulk manufacture of the substance an opportunity
for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on January 20, 2006, Lipomed Inc., One Broadway, Cambridge, Massachusetts
02142, made application, by letter and by renewal, to the Drug Enforcement
Administration (DEA) to be registered as an Importer in the basic classes of
controlled substances in Schedule I and II:
|
Drug
|
Schedule
|
|
Cathinone (1235)
|
I
|
|
Methcathinone (1237)
|
I
|
|
N-Ethylamphetamine (1475)
|
I
|
|
Methaqualone (2565)
|
I
|
|
Gamma-Hydroxybutyric Acid (2010)
|
I
|
|
Lysergic acid diethylamide (7315)
|
I
|
|
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)
|
I
|
|
Marihuana (7360)
|
I
|
|
Tetrahydrocannabinols (7370)
|
I
|
|
Mescaline (7381)
|
I
|
|
3,4,5-Trimethoxyamphetamine (7390)
|
I
|
|
4-Bromo-2-5-dimethoxyamphetamine (7391)
|
I
|
|
4-Bromo-2,5-dimethoxyphyenethylamine (7392)
|
I
|
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
|
2,5-Dimethoxy-4-ethylamphetamine (7399)
|
I
|
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
|
3,4-Methylenedioxymethamphetamine (7405)
|
I
|
|
[[Page 41838]]
|
|
|
4-Methoxyamphetamine (7411)
|
I
|
|
Dimethyltryptamine (7435)
|
I
|
|
Psilocybin (7437)
|
I
|
|
Psilocyn (7438)
|
I
|
|
Acetyldihydrocodeine (9051)
|
I
|
|
Dihydromorphine (9145)
|
I
|
|
Heroin (9200)
|
I
|
|
Normorphine (9313)
|
I
|
|
Pholcodine (9314)
|
I
|
|
Tilidine (9750)
|
I
|
|
Amphetamine (1100)
|
II
|
|
Methamphetamine (1105)
|
II
|
|
Amobarbital (2125)
|
II
|
|
Pentobarbital (bulk) (2270)
|
II
|
|
Secobarbital (2315)
|
II
|
|
Phencyclidine (7471)
|
II
|
|
Cocaine (9041)
|
II
|
|
Codeine (9050)
|
II
|
|
Dihydrocodeine (9120)
|
II
|
|
Oxycodone (9143)
|
II
|
|
Hydromorphone (9150)
|
II
|
|
Benzoylecgonine (9180)
|
II
|
|
Ethylmorphine (9190)
|
II
|
|
Hydrocodone (9193)
|
II
|
|
Levorphanol (9220)
|
II
|
|
Meperidine (9230)
|
II
|
|
Methadone (9250)
|
II
|
|
Dextropropoxyphene, bulk (9273)
|
II
|
|
Morphine (9300)
|
II
|
|
Thebaine (9333)
|
II
|
|
Oxymorphone (9652)
|
II
|
|
Alfentanil (9737)
|
II
|
|
Fentanyl (9801)
|
II
|
|
Sufentanil (9740)
|
II
|
The company plans to import analytical reference standards for distribution
to its customers for research and analytical purposes.
Any manufacturer who is presently, or is applying to be, registered with DEA
to manufacture such basic classes of controlled substances may file comments or
objections to the issuance of the proposed registration and may, at the same
time, file a written request for a hearing on such application pursuant to 21
CFR 1301.43 and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or objections being sent via regular mail may be
addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, Washington, DC 20537,
Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL);
or any being sent via express mail should be sent to DEA Headquarters,
Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis
Highway, Alexandria, Virginia 22301; and must be filed no later than August 23,
2006.
This procedure is to be conducted simultaneously with and independent of the
procedures described in 21
CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice
published in the Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled substance
listed in Schedule I or II are, and will continue to be required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, that the requirements for such registration pursuant
to 21 U.S.C. 958(a),
21 U.S.C. 823(a),
and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: July 10, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-11688 Filed 7-21-06; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|